Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 20;9:13613. doi: 10.1038/s41598-019-49894-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Regulation of PTM relative abundance and labeling rate upon drug treatment. (A) Relative abundance of the most abundant acetylations of histone H3 and H4 in wild type and HDAC inhibitor (HDACi) treated cells. (B) Relative abundance of representative modified forms of histone H3 regulated during treatment with inhibitors. All data were extracted after 2 days of labeling. All significance estimations are based on a two-tail heteroscedastic t-test (significant when p-value < 0.05). (C) Correlation analysis of fold change regulation (not significant) of the relative abundance of histone peptides after treating cells with EZH2 inhibitor (x-axis) vs the fold change of labeling incorporation (y-axis). The y-axis shows very minor changes, indicating that the regulation of PTM abundance is independent from the labeling incorporation. (D) Same correlation analysis using the HDAC inhibitor Panobinostat (not significant). (E) Labeling incorporation of the major acetylated peptides of histone H3 and H4 in wild type and HDACi treated cells.